IC-351: Treatment of erectile dysfunction treatment of female sexual dysfunction phosphodiesterase 5 inhibitor

Drugs of the Future

Volumn 26, Issue 1, 2001, Pages 15-19

  Sorbera, L A ^a   Martin L ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; 6 (1,3 BENZODIOXOL 5 YL) 2 METHYL 1,2,3,4,6,7,12,12A OCTAHYDROPYRAZINO[2',1':6,1]PYRIDO[3,4 B]INDOLE 1,4 DIONE; BMS 341400; E 8010; EMD 221829; FR 229934; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TA 1790; TADALAFIL; UDENAFIL; UK 343664; UK 357903; UNCLASSIFIED DRUG; VARDENAFIL;

ADULT; ARTICLE; BACKACHE; CHEMICAL ANALYSIS; CHEMICAL REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; MYALGIA; PLETHYSMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REACTION ANALYSIS;

EID: 0035107498     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.01.606182     Document Type: Article

References (13)

1. The epidemiology of erectile dysfunction
2. Cyclic GMP phosphodiesterase-5: Target of sildenafil
3. New therapies and delivery mechanisms for treatment of erectile dysfunction
4. Daily IC351 treatment of erectile dysfunction
5. On-demand treatment of erectile dysfunction with IC351
6. Efficacy and safety of IC351 treatment for erectile dysfunction
7. Effect of IC351 on erectile response to visual sexual stimulation
8. ICOS science